黑色素瘤
免疫系统
免疫原性
预酸化
癌症研究
GTP酶
生物
免疫学
免疫检查点
免疫疗法
医学
细胞生物学
生物化学
酶
作者
Guillaume Sarrabayrouse,Christine Pich-Bavastro,Iotefa Teiti,Anne Françoise Tilkin‐Mariame
摘要
Melanoma is a highly lethal cutaneous tumor, killing affected patients through development of multiple poorly immunogenic metastases. Suboptimal activation of immune system by melanoma cells is often due to molecular modifications occurring during tumor progression that prevent efficient recognition of melanoma cells by immune effectors. Statins are HMG‐CoA reductase inhibitors, which block the mevalonate synthesis pathway, used by millions of people as hypocholesterolemic agents in cardiovascular and cerebrovascular diseases. They are also known to inhibit Rho GTPase activation and Rho dependent signaling pathways. Rho GTPases are regarded as molecular switches that regulate a wide spectrum of cellular functions and their dysfunction has been characterized in various oncogenic process notably in melanoma progression. Moreover, these molecules can modulate the immune response. Since 10 years we have demonstrated that Statins and other Rho GTPases inhibitors are critical regulators of molecules involved in adaptive and innate anti‐melanoma immune response. In this review we summarize our major observations demonstrating that these pharmacological agents stimulate melanoma immunogenicity and suggest a potential use of these molecules to promote anti‐melanoma immune response.
科研通智能强力驱动
Strongly Powered by AbleSci AI